Chinese researchers develop probiotic yoghurt that could replace diabetes injections

Researchers have created an engineered probiotic strain called Gift that could transform diabetes management by eliminating the need for regular insulin injections. The organism works by monitoring blood glucose levels and releasing glucagon-like peptide-1 (GLP-1), a hormone that naturally regulates blood sugar, when elevated levels are detected.

Preliminary testing in animal models has demonstrated that the probiotic delivers therapeutic effects comparable to semaglutide, the active ingredient in popular injectable diabetes treatments. The approach leverages the gut microbiome as a delivery mechanism, allowing the beneficial bacteria to continuously monitor metabolic conditions and respond with hormone production.

The development represents a significant shift in diabetes treatment philosophy, moving away from external pharmaceutical intervention toward internal biological regulation. If successful in human trials, such engineered probiotics could offer diabetic patients a more convenient oral alternative while potentially reducing the cost and complexity associated with regular injections.

The research underscores China's growing investment in precision medicine and biotechnology innovation. However, regulatory approval and extensive human clinical trials will be required before the probiotic can reach patients, with researchers needing to confirm its safety, efficacy, and stability in the human digestive system.

Experts in endocrinology note that engineered probiotics represent a promising frontier in treating chronic metabolic diseases, though significant work remains to translate laboratory success into practical, scalable medical treatments.